UNLABELLED: Hypertension and hypothyreoidism are frequent side effects of VEGFR-inhibitors. We investigated whether hypertension or hypothyreoidism diagnosed during sunitinib treatment is associated with treatment efficacy. MATERIAL AND METHODS: Sixty-four consecutive patients with metastatic renal cell cancer (RCC) were treated with sunitinib in a single center. Hypertension was defined as persistent blood pressure >150/100 mmHg or blood pressure requiring intensification of pre-existing anti-hypertensive medication. Hypothyreoidism was defined as elevation of TSH levels and clinical symptoms requiring hormone replacement therapy (≥Gr. II hypothyreoidim). RESULTS: Twenty-four (38%) patients developed hypertension and 12 (19%) hypothyreoidism. The dose of sunitinib administered was not significantly associated with hypertension or hypothyreoidism. There was no correlation between hypertension and hypothyreoidism. Hypertension was associated with frequent tumor response to sunitinib, a long time to disease progression and long overall survival (p= 0.001, 0.0003 and 0.001, respectively). In a multivariate analysis, hypertension was an independent predictor of progression-free survival (hazard ratio, 0.21; 95% CI 0.076 to 0.59, p=0.0030). There were no statistically significant differences in the frequency of ≥ grade 3 adverse events between patients with or without hypertension. CONCLUSION: Sunitinib-associated hypertension may be a strong predictive marker for treatment efficacy in metastatic RCC.
UNLABELLED: Hypertension and hypothyreoidism are frequent side effects of VEGFR-inhibitors. We investigated whether hypertension or hypothyreoidism diagnosed during sunitinib treatment is associated with treatment efficacy. MATERIAL AND METHODS: Sixty-four consecutive patients with metastatic renal cell cancer (RCC) were treated with sunitinib in a single center. Hypertension was defined as persistent blood pressure >150/100 mmHg or blood pressure requiring intensification of pre-existing anti-hypertensive medication. Hypothyreoidism was defined as elevation of TSH levels and clinical symptoms requiring hormone replacement therapy (≥Gr. II hypothyreoidim). RESULTS: Twenty-four (38%) patients developed hypertension and 12 (19%) hypothyreoidism. The dose of sunitinib administered was not significantly associated with hypertension or hypothyreoidism. There was no correlation between hypertension and hypothyreoidism. Hypertension was associated with frequent tumor response to sunitinib, a long time to disease progression and long overall survival (p= 0.001, 0.0003 and 0.001, respectively). In a multivariate analysis, hypertension was an independent predictor of progression-free survival (hazard ratio, 0.21; 95% CI 0.076 to 0.59, p=0.0030). There were no statistically significant differences in the frequency of ≥ grade 3 adverse events between patients with or without hypertension. CONCLUSION:Sunitinib-associated hypertension may be a strong predictive marker for treatment efficacy in metastatic RCC.
Authors: Cody N Justice; Mohamed H Derbala; Tesla M Baich; Amber N Kempton; Aaron S Guo; Thai H Ho; Sakima A Smith Journal: J Cardiovasc Pharmacol Ther Date: 2018-04-29 Impact factor: 2.457
Authors: Piotr Rutkowski; Elżbieta Bylina; Anna Klimczak; Tomasz Switaj; Sławomir Falkowski; Jacek Kroc; Iwona Lugowska; Magdalena Brzeskwiniewicz; Wojciech Melerowicz; Czesław Osuch; Ewa Mierzejewska; Kacper Wasielewski; Agnieszka Woźniak; Urszula Grzesiakowska; Zbigniew I Nowecki; Janusz A Siedlecki; Janusz Limon Journal: BMC Cancer Date: 2012-03-22 Impact factor: 4.430
Authors: Dave Lengel; Eva Lamm Bergström; Herb Barthlow; Karen Oldman; Helen Musgrove; Alex Harmer; Jean-Pierre Valentin; Paul Duffy; Martin Braddock; Jon Curwen Journal: Pharmacol Res Perspect Date: 2015-09-15
Authors: Petri Bono; Stephane Oudard; Istvan Bodrogi; Thomas E Hutson; Bernard Escudier; Jean-Pascal Machiels; John A Thompson; Robert A Figlin; Alain Ravaud; Mert Basaran; Camillo Porta; Sergio Bracarda; Thomas Brechenmacher; Chinjune Lin; Maurizio Voi; Viktor Grunwald; Robert J Motzer Journal: Clin Genitourin Cancer Date: 2016-04-27 Impact factor: 2.872